Skip to content

Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.

Jacob Cohen, Peter Parbo, Per Trads Ørskov, Dirk Wildgruber, Benjamin Kreifelts, Ulrich Kirk, Oke Gerke, Martin Korsbak Madsen, Mikael Palner

PsyArXiv May 14, 2026 preprint DOI: 10.31234/osf.io/3b9fx_v1 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Double-blind
Population People with social anxiety disorder
Interventions Psilocybin Virtual reality exposure therapy
Dose low doses
Topics Anxiety Psilocybin
Key findings The protocol outlines a planned trial to evaluate psilocybin as an adjunct to virtual reality exposure therapy for social anxiety disorder; no findings are reported.

Abstract

Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.

Related reading